Immune-Marker Platform for Patients With Advanced Lung Cancer
This study aims to understand how your immune system and specific markers in your tumour affect how you respond to treatment for advanced non-small cell lung cancer (NSCLC). Doctors want to see if they can identify special signals within your tumour that predict whether a treatment will be effective. This isn't a new drug trial; instead, it's about learning more from existing treatments to help future patients. By studying small samples of your tumour before, during, and after treatment, researchers hope to find better ways to personalise treatment plans and improve care for people with this type of lung cancer.
Överblick
Vad handlar denna studie om?
This research study is about understanding advanced non-small cell lung cancer (NSCLC) better. NSCLC is a common type of lung cancer, and 'advanced' means it has spread or is difficult to treat with surgery alone. The study focuses on a specific type of treatment called immunochemotherapy, which combines chemotherapy (drugs that kill cancer cells) with immunotherapy (drugs that help your own immune system fight cancer).
The main goal is to figure out if there are certain 'markers' in your tumour or in your immune system that can tell us how well a patient might respond to this treatment. Think of these markers like clues; by finding these clues, doctors hope to predict who will benefit most from immunochemotherapy and understand why some treatments work better for some people than others. This isn't about testing a brand-new medicine, but rather about learning more from treatments already in use to improve future care.
Researchers will look at tiny bits of your tumour tissue to see what's happening inside – for example, what genes are active or how your immune cells are behaving. They will then compare these findings with how patients respond to their treatment. This will help them to understand the disease and its treatments in a more detailed way, potentially leading to more personalised and effective care for people with advanced lung cancer in the future.
Viktiga punkter
- This study helps doctors understand advanced lung cancer better.
- It's about studying existing immunochemotherapy treatments, not new ones.
- Researchers look for 'markers' in your tumour to predict treatment response.
- You would provide small tumour samples (biopsies) at key times.
- This research aims to improve future care for lung cancer patients.
Vem kan vara berättigad?
This study is for adults aged 18 or over who have advanced non-small cell lung cancer (NSCLC) that can't be cured. You must not have certain common genetic changes in your cancer that can be targeted with other specific drugs. Also, your cancer's PD-L1 expression (a marker related to how immunotherapy works) must be less than 50%.
There are two groups in the study. If you're in Cohort A, you haven't started treatment for your advanced lung cancer yet. If you're in Cohort B, you've already had first-line immunochemotherapy and your cancer has progressed.
You cannot take part if a doctor thinks getting an extra tumour sample would be too risky for you, or if you can't understand what the study involves. Certain issues like drug or alcohol misuse, or other medical/mental health conditions that might stop you from taking part safely, would also prevent you from joining.
Kan denna studie passa dig?
Svara på dessa snabba frågor för att se om du kan vara berättigad. Detta är endast en vägledning — forskarteamet fattar det slutgiltiga beslutet.
- Är du 18 år eller äldre?
- Do you have advanced non-small cell lung cancer that cannot be cured?
- Does your cancer not have certain common genetic changes that can be treated with targeted drugs?
- Do you have a PD-L1 expression on your tumour cells of less than 50%?
- Are you able and willing to have tumour biopsies as required by the study?
Vad innebär deltagande?
If you decide to take part in this study, you'll be asked to provide small samples of your tumour tissue. This will usually involve a procedure called a biopsy. You would have a biopsy before you start your immunochemotherapy, another one about six weeks after starting treatment, and potentially another if your cancer progresses or your treatment changes. These samples will be analysed by researchers in a laboratory to look for immune and genetic markers. You'll also be asked to share information about your treatment response and how your illness is progressing, which the researchers will link to the findings from your tumour samples. This study does not involve taking any new medications or treatments; it's about studying the treatments you are already receiving.
Potentiella risker och fördelar
Platser (2)
- Universitätsklinikum Köln, Centrum für Integrierte Onkologie (CIO) KölnVerifierat postnummerKöln, Tyskland
- Universitätsklinikum Carl Gustav CarusVerifierat postnummerDresden, Tyskland
Vanliga frågor
What kind of lung cancer is this study about?
It's about advanced non-small cell lung cancer (NSCLC), which is a common type of lung cancer that has spread or is difficult to cure with surgery.
Kommer jag att få en ny behandling i denna studie?
No, this study isn't testing new treatments. It's about learning more from the treatments you're already receiving, specifically immunochemotherapy.
What does 'immune-marker' mean?
It refers to special signals or characteristics in your tumour or immune system that doctors hope can predict how you'll respond to treatment.
Vad måste jag göra om jag går med?
You'll provide small tumour samples (biopsies) at different times during your treatment, and share information about how your cancer is responding.
Will this study directly help me?
Not directly at the time of the study, as it's for research. But the information gained could lead to better treatments and care for others with lung cancer in the future.
Hur du får reda på mer
Martin Wermke, Prof. Dr.
Prata alltid med din läkare eller specialist innan du bestämmer dig för att delta i en studie.
Intresserad av att delta?
Diskussion
Gemenskapsdiskussion
Drivs av vårt forum på community.patient.info. Var vänlig och respektfull — detta är inte medicinsk rådgivning.